An observational study in Pulmonary Embolism, sponsored by Sohag University. Recruiting at 2 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Sohag University · Observational
This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.
This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
This study's planned enrollment of 112 is below the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Browse Pulmonary Embolism studies →Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed as acute pulmonary embolism
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients diagnosed with acute pulmonary embolism who undergo transthoracic echocardiographic assessment for evaluation of right ventricular dysfunction.
Other: Transthoracic Echocardiography
Transthoracic echocardiography performed for assessment of right ventricular dysfunction in patients with acute pulmonary embolism.
Right ventricular dysfunction as a prognostic marker in acute pulmonary embolism
To assess the prognostic value of right ventricular dysfunction detected by transthoracic echocardiography for risk stratification in patients with acute pulmonary embolism
Time frame: From hospital admission until hospital discharge, with an average duration of 7 days.
In-hospital adverse clinical outcomes
To evaluate the occurrence of in-hospital adverse clinical outcomes, including respiratory failure, hemodynamic instability, cardiac arrhythmias, intensive care unit admission, and mortality, and their association with right ventricular dysfunction in patients with acute pulmonary embolism
Time frame: From hospital admission until hospital discharge, with an average duration of 7 days.
Plan to share: Undecided — Individual participants data sharing plans are currently undecided
Start is estimated for Jun 2026; primary completion for Nov 2026, 5 months later.
Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's planned 5 months is below that.
Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.